AbbVie (ABBV) director granted 1,118 restricted stock units as equity pay

Rhea-AI Filing Summary

Roberts Rebecca B reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Rebecca B. Roberts received a grant of 1,118 shares of common stock in the form of restricted stock units. These units were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program and carry a zero-dollar grant price. After this grant, she directly holds 14,846 shares. The units will be settled on a one‑for‑one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Roberts Rebecca B

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value	1,118	$0.00	--

Holdings After Transaction: Common Stock, $0.01 par value — 14,846 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 1,118 units Grant price per share: $0.00 Total shares after grant: 14,846 shares

3 metrics

RSU grant size 1,118 units Restricted stock units awarded to director on 2026-05-08

Grant price per share $0.00 Equity award under 2013 Incentive Stock Program

Total shares after grant 14,846 shares Director’s direct AbbVie holdings following the transaction

Key Terms

restricted stock units, Incentive Stock Program, change in control

3 terms

restricted stock units financial

"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Incentive Stock Program financial

"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Rebecca B

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	05/08/2026		A		1,118(1)	A	$0	14,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ T.O. Odutayo, Attorney-in-Fact for Rebecca B. Roberts	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AbbVie (ABBV) report for Rebecca B. Roberts?

AbbVie reported that director Rebecca B. Roberts received 1,118 restricted stock units. These units were granted under the company’s 2013 Incentive Stock Program as equity compensation and will convert into AbbVie common shares upon specific future events.

How many AbbVie shares does Rebecca B. Roberts hold after this Form 4 transaction?

After the grant, Rebecca B. Roberts directly holds 14,846 AbbVie common shares. This total includes the newly awarded 1,118 restricted stock units, which will later be settled in shares upon separation from service, death, or a qualifying change in control event.

What type of equity award did AbbVie (ABBV) grant to director Rebecca B. Roberts?

AbbVie granted Rebecca B. Roberts restricted stock units under its Amended and Restated 2013 Incentive Stock Program. Each unit represents a right to receive one AbbVie common share upon specified triggering events rather than an immediate cash payment or open‑market stock purchase.

When will Rebecca B. Roberts’ AbbVie restricted stock units be paid out?

The restricted stock units will be paid out in AbbVie common stock on a one‑to‑one basis. Payment occurs at the earlier of her separation from service, her death, or a change in control, as those terms are defined in AbbVie’s 2013 Incentive Stock Program.

Did Rebecca B. Roberts buy or sell AbbVie shares on the open market?

No open‑market buy or sell occurred in this filing. The Form 4 reports a grant of 1,118 restricted stock units at a zero-dollar price as part of AbbVie’s director compensation, rather than a discretionary market purchase or sale of existing AbbVie shares.